News | May 27, 2010

Study Reveals 86.2 Percent SFA Patency With Self-Expanding DES

May 27, 2010 – One-year data presented this week at EuroPCR in Paris confirms sustained clinical outcomes with Cook Medical's drug-eluting peripheral stent, Zilver PTX. According to data presented by professor Dierk Scheinert, medical director at Park Hospital Leipzig, 86.2 percent of all patient subgroups treated with Zilver PTX drug-eluting stent (DES) demonstrated vessel patency at 12 months without the requirement for an additional intervention.

The data were collected as part of the world's largest clinical study of endovascular treatment for peripheral arterial disease (PAD) in the superficial femoral artery (SFA). The trial is based on a group of 787 patients, including symptomatic patients, diabetics, and those with the most complex lesions, including long lesions, total occlusions and in-stent restenosis.

The single-arm study also revealed:
• A low stent fracture rate of 1.5 percent
• On average a greater than 50 percent reduction in restenosis compared to published studies on bare-metal and other DES
• Improved clinical outcomes at 12 months according to all four key clinical indicators (ankle-brachial index, Rutherford Score, walking speed and walking distance)

"I think the patency data look great. A greater than 50 percent reduction of restenosis is quite impressive and surprising in a positive way," said Scheinert, a clinical investigator in the trial. "I'm looking forward to the final data from the randomized study, which could confirm this as a major step forward in treating severe lesions within the SFA."

Regulatory Clearance
Angiotech, the maker of the paclitaxel antiproliferative drug used on the Zilver stent, said the optimistic results of this trial will support Cook's application with the U.S. Food and Drug Administration (FDA). If cleared, it will become the first drug-coated peripheral stent available in the United States.
The Zilver PTX stent was CE marked in August 2009 and has been made available in Europe since September of 2009. It is the first drug-eluting stent indicated for treating PAD in the SFA in the leg.

Upon deployment, the Zilver PTX stent expands and holds open the artery to restore blood flow. It then delivers the drug paclitaxel to the cells in the vessel wall to reduce the risk of new blockages forming. In a major advance over previous drug-eluting technologies, the Zilver PTX achieves targeted drug delivery without using a polymer to adhere the drug to the stent body. This eliminates the potential patient risks associated with polymer-coated devices, including clot formation and inflammation.

For more information:

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init